Insights

Every major drug facing generic competition is a battlefield. The weapon of choice is not chemistry or clinical data—it is […]

Branded generics occupy a middle ground between expensive branded drugs and bare-bones unbranded generics. These products use off-patent active ingredients

The pharmaceutical industry has long been viewed through a binary lens. On one side, the high-stakes, high-margin world of patented

An investigative analysis of the business architecture behind pharma’s most durable profit model When Pfizer’s patent on atorvastatin expired in

The maturation of algorithmic discovery The pharmaceutical industry reached an inflection point in 2025 as artificial intelligence transitioned from a

The pharmaceutical industry is struggling with its own productivity. The cost of bringing a single new chemical entity to market

1. The Economics of Managed Exclusivity The pharmaceutical industry operates on a unique economic premise: huge upfront investment in research

Executive Summary The pharmaceutical sector currently faces a distinct legal friction where federal health policy conflicts with intellectual property statutes.

Executive Summary The biopharmaceutical and life sciences sectors face a central, defining strategic tension: the optimal allocation of capital between